GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway

Few studies have focused on ?-aminobutyric acid type A (GABAA) receptor-associated protein (GABARAP) in tumor progression. We investigated the expression and importance of GABARAP breast cancer. analyzed its relationship with clinicopathological features prognosis (TCGA). To explain role potential mechanism regulating development, we performed acquisition loss function experiments using cell lines models mouse xenotransplantation. found that inhibited proliferation, migration invasion vitro vivo. Notably, low levels induced epithelial-mesenchymal transition (EMT). Low increased p-AKT p-mTOR levels, a specific AKT pathway inhibitor reversed downregulation GABARAP-induced negatively correlated advanced clinical specimens, such as size TNM stage. patients had poor prognosis. Immunohistochemistry (IHC) revealed matrix metalloproteinase (MMP) 2 MMP14. Conclusively, these data indicate suppresses malignant behaviors cancer likely via AKT/mTOR pathway. The targeting may improve certainty diagnosis treatment strategies for